• CSE: DTC
  • FSE: DTC
  • USOTC: DTCFF
  • Download our Corporate Deck
  • GER
  • ENG
Defence Therapeutics
  • About Us
    • Our Model
    • Leaders & Partnerships
  • Accum Technology
    • Platform Technology
    • Cancer Therapeutics
    • Vaccine Development
  • Investors
  • News
  • Contact
Select Page
Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million

Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million

by Defence Therapeutics | May 30, 2023 | News Release

Vancouver, BC, Canada, May 26th, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that, in...
Breakthrough Results: Defences Arm Vaccine Cured 100% of Animals with Pre-established Lymphoma

Breakthrough Results: Defences Arm Vaccine Cured 100% of Animals with Pre-established Lymphoma

by FiveSenses | May 24, 2023 | News Release

Vancouver, BC, Canada, May 24th 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful...
Defence’s Successful Accutox™ Pre-Clinical Efficacy Study Complete Ready for Phase I and Filing

Defence’s Successful Accutox™ Pre-Clinical Efficacy Study Complete Ready for Phase I and Filing

by FiveSenses | May 2, 2023 | News Release

Vancouver, BC, Canada, May 2nd, 2023 – Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immuneoncology vaccines and drug delivery technologies is please to announce the successful...

Recent Posts

  • Defence’s Broad and Versatile Accum® Technology Platform Focus on Cancer Therapeutics
  • Defence’s Innovative Therapeutics are Featured on Viewpoint with Dennis Quaid 
  • Defence Successfully Completes The First Milestone of its Collaboration Agreement with Orano
  • Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthrough in Biotechnology
  • Defence Patent Portfolio at the Forefront of Success

Recent Comments

    Archives

    • September 2023
    • July 2023
    • June 2023
    • May 2023
    • April 2023

    Categories

    • News Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Stock

    CSE: DTC
    FSE: DTC
    USOTC: DTCFF

    Contact

    (514) 947 – 2272
    info@defencetherapeutics.com

    1680 – 200 Burrard Street, Vancouver, BC, V6C 3L6

    Copyright © 2020. Defence Therapeutics. All Rights Reserved. / Web Design by Five Senses Branding